Porcine Partial Liver Transplantation Without Veno-venous Bypass: An Effective Model for Small-for-Size Liver Graft Injury

2011 ◽  
Vol 43 (5) ◽  
pp. 1953-1961 ◽  
Author(s):  
Y. Fu ◽  
H.-B. Zhang ◽  
N. Yang ◽  
N. Zhu ◽  
H. Si-Ma ◽  
...  
2004 ◽  
Vol 10 (2) ◽  
pp. 253-263 ◽  
Author(s):  
Dympna M. Kelly ◽  
A. Jake Demetris ◽  
John J. Fung ◽  
Amadeo Marcos ◽  
Yue Zhu ◽  
...  

2013 ◽  
Vol 27 (1) ◽  
pp. 106-113 ◽  
Author(s):  
Takuya Yoichi ◽  
Tsukasa Takayashiki ◽  
Hiroaki Shimizu ◽  
Hiroyuki Yoshidome ◽  
Masayuki Ohtsuka ◽  
...  

BMC Surgery ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Stefan M. Brunner ◽  
Frank W. Brennfleck ◽  
Henrik Junger ◽  
Jirka Grosse ◽  
Birgit Knoppke ◽  
...  

Abstract Background Risks for living-liver donors are lower in case of a left liver donation, however, due to lower graft volume, the risk for small-for-size situations in the recipients increases. This study aims to prevent small-for-size situations in recipients using an auxiliary two-staged partial resection liver transplantation (LTX) of living-donated left liver lobes. Case presentation Two patients received a two-stage auxiliary LTX using living-donated left liver lobes after left lateral liver resection. The native extended right liver was removed in a second operation after sufficient hypertrophy of the left liver graft had occurred. Neither donor developed postoperative complications. In both recipients, the graft volume increased by an average of 105% (329 ml to 641 ml), from a graft-to-body-weight ratio of 0.54 to 1.08 within 11 days after LTX, so that the remnant native right liver could be removed. No recipient developed small-for-size syndrome; graft function and overall condition is good in both recipients after a follow-up time of 25 months. Conclusions Auxiliary two-staged partial resection LTX using living-donor left lobes is technically feasible and can prevent small-for-size situation. This new technique can expand the potential living-donor pool and contributes to increase donor safety.


2012 ◽  
Vol 48 (3) ◽  
pp. 163-170 ◽  
Author(s):  
S. Yagi ◽  
T. Iida ◽  
T. Hori ◽  
K. Taniguchi ◽  
M. Nagahama ◽  
...  

2009 ◽  
Vol 15 (2) ◽  
pp. 163-168 ◽  
Author(s):  
Abhinav Humar ◽  
Joy Beissel ◽  
Shaina Crotteau ◽  
Melissa Cohen ◽  
John Lake ◽  
...  

HPB Surgery ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-13 ◽  
Author(s):  
Qinlong Liu ◽  
Hasibur Rehman ◽  
Russell A. Harley ◽  
John J. Lemasters ◽  
Zhi Zhong

Pulmonary complications after liver transplantation (LT) often cause mortality. This study investigated whether small-for-size LT increases acute pulmonary injury and whether NIM811 which improves small-for-size liver graft survival attenuates LT-associated lung injury. Rat livers were reduced to 50% of original size, stored in UW-solution with and without NIM811 (5 μM) for 6 h, and implanted into recipients of the same or about twice the donor weight, resulting in half-size (HSG) and quarter-size grafts (QSG), respectively. Liver injury increased and regeneration was suppressed after QSG transplantation as expected. NIM811 blunted these alterations >75%. Pulmonary histological alterations were minimal at 5–18 h after LT. At 38 h, neutrophils and monocytes/macrophage infiltration, alveolar space exudation, alveolar septal thickening, oxidative/nitrosative protein adduct formation, and alveolar epithelial cell/capillary endothelial apoptosis became overt in the lungs of QSG recipients, but these alterations were mild in full-size and HSG recipients. Liver pretreatment with NIM811 markedly decreased pulmonary injury in QSG recipients. Hepatic TNFα and IL-1β mRNAs and pulmonary ICAM-1 expression were markedly higher after QSG transplantation, which were all decreased by NIM811. Together, dysfunctional small-for-size grafts produce toxic cytokines, leading to lung inflammation and injury. NIM811 decreased toxic cytokine formation, thus attenuating pulmonary injury after small-for-size LT.


2020 ◽  
Vol 20 (9) ◽  
pp. 720-727
Author(s):  
Jianguo Qiu ◽  
Wei Tang ◽  
Chengyou Du

Background: Immune checkpoint modulators, such as the programmed death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor, cytotoxic T-Lymphocyte-associated antigen 4 (CTLA-4) inhibitor have been investigated with encouraging results for hepatocellular carcinoma (HCC). However, the safety of this strategy in patients with previous liver transplantation (LT) is not well studied. Objective: To explore the safety and feasibility of immune checkpoints inhibitors in recurrent and metastatic HCC patients on a background of LT. Methods: A case of recurrent, refractory, metastatic HCC after LT, where PD-1 inhibitor was initiated, was described and related literature was reviewed. Results: There was complete remission in lung metastases and the partial radiological response of metastatic retroperitoneal lymph node to the drug with no liver graft rejection after 13 cycles of PD- 1 inhibitor injection. PD-1inhibitor, at least in this patient, was verified to play an important role in controlling tumor progression and prolonging patient survival. Conclusions: This novel drug might be a useful method to allow doctors to guarantee a better chance for long-term survival in recurrent, metastatic HCC patients with the previous LT. However, it should be used with caution in allograft recipients due to the risk of acute graft rejection, further larger, prospective studies are needed to determine optimal immunomodulatory therapy to achieve optimal anti-tumor efficacy with transplant liver preservation.


Sign in / Sign up

Export Citation Format

Share Document